Pascaline Bouzy1, Shane O'Grady2, Honey Madupalli3, Mary Tecklenburg3, Keith Rogers4, Francesca Palombo1, Maria P Morgan2, Nicholas Stone5. 1. School of Physics and Astronomy, University of Exeter, Exeter, UK. 2. School of Pharmacy and Biomolecular Science, Royal College of Surgeons in Ireland, Dublin, 2, Ireland. 3. Department of Chemistry and Biochemistry and Science of Advanced Materials Program, Central Michigan University, Mt. Pleasant, MI, USA. 4. Cranfield Forensic Institute, Cranfield University, Shrivenham, UK. 5. School of Physics and Astronomy, University of Exeter, Exeter, UK. n.stone@exeter.ac.uk.
Abstract
Microcalcifications are early markers of breast cancer and can provide valuable prognostic information to support clinical decision-making. Current detection of calcifications in breast tissue is based on X-ray mammography, which involves the use of ionizing radiation with potentially detrimental effects, or MRI scans, which have limited spatial resolution. Additionally, these techniques are not capable of discriminating between microcalcifications from benign and malignant lesions. Several studies show that vibrational spectroscopic techniques are capable of discriminating and classifying breast lesions, with a pathology grade based on the chemical composition of the microcalcifications. However, the occurrence of microcalcifications in the breast and the underlying mineralization process are still not fully understood. Using a previously established model of in vitro mineralization, the MDA-MB-231 human breast cancer cell line was induced using two osteogenic agents, inorganic phosphate (Pi) and β-glycerophosphate (βG), and direct monitoring of the mineralization process was conducted using Raman micro-spectroscopy. MDA-MB-231 cells cultured in a medium supplemented with Pi presented more rapid mineralization (by day 3) than cells exposed to βG (by day 11). A redshift of the phosphate stretching peak for cells supplemented with βG revealed the presence of different precursor phases (octacalcium phosphate) during apatite crystal formation. These results demonstrate that Raman micro-spectroscopy is a powerful tool for nondestructive analysis of mineral species and can provide valuable information for evaluating mineralization dynamics and any associated breast cancer progression, if utilized in pathological samples.
Microcalcifications are early markers of pan class="Disease">breast cancer and can provide valuable prognostic information to support clinical decision-making. Current detection of calcifications in breast tissue is based on X-ray mammography, which involves the use of ionizing radiation with potentially detrimental effects, or MRI scans, which have limited spatial resolution. Additionally, these techniques are not capable of discriminating between microcalcifications from benign and malignant lesions. Several studies show that vibrational spectroscopic techniques are capable of discriminating and classifying breast lesions, with a pathology grade based on the chemical composition of the microcalcifications. However, the occurrence of microcalcifications in the breast and the underlying mineralization process are still not fully understood. Using a previously established model of in vitro mineralization, the MDA-MB-231humanbreast cancer cell line was induced using two osteogenic agents, inorganic phosphate (Pi) and β-glycerophosphate (βG), and direct monitoring of the mineralization process was conducted using Raman micro-spectroscopy. MDA-MB-231 cells cultured in a medium supplemented with Pi presented more rapid mineralization (by day 3) than cells exposed to βG (by day 11). A redshift of the phosphate stretching peak for cells supplemented with βG revealed the presence of different precursor phases (octacalcium phosphate) during apatite crystal formation. These results demonstrate that Raman micro-spectroscopy is a powerful tool for nondestructive analysis of mineral species and can provide valuable information for evaluating mineralization dynamics and any associated breast cancer progression, if utilized in pathological samples.
Authors: Abigail S Haka; Karen E Shafer-Peltier; Maryann Fitzmaurice; Joseph Crowe; Ramachandra R Dasari; Michael S Feld Journal: Cancer Res Date: 2002-09-15 Impact factor: 12.701
Authors: L Frappart; M Boudeulle; J Boumendil; H C Lin; I Martinon; C Palayer; Y Mallet-Guy; D Raudrant; A Bremond; Y Rochet Journal: Hum Pathol Date: 1984-09 Impact factor: 3.466